Esperoct, also known by its generic name efmoroctocog alfa, is a recombinant coagulation factor VIII (FVIII) used to treat and control bleeding in individuals with hemophilia A [1]. It is a modified form of FVIII designed to have a longer half-life, meaning it stays in the bloodstream for a longer duration compared to earlier FVIII treatments [2].
How long does Esperoct stay active in the body?
Esperoct's extended half-life allows for less frequent dosing. For routine prophylaxis, the recommended dose is typically 50 international units per kilogram (IU/kg) of body weight administered once weekly [1]. This extended duration of action is a key therapeutic advantage.
How does Esperoct work for hemophilia A?
Hemophilia A is an inherited bleeding disorder caused by a deficiency in functional clotting factor VIII. Esperoct is a recombinant form of human FVIII, which means it is produced in a laboratory using genetic engineering. When administered, it replaces the missing or deficient FVIII, enabling blood to clot properly and reducing the risk of spontaneous or prolonged bleeding [1].
What are the approved uses for Esperoct?
Esperoct is approved for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A, including those who are previously treated [1]. It can also be used for on-demand treatment to control bleeding episodes and for perioperative management in patients with hemophilia A [3].
When might Esperoct's patent protection end?
Patent expiry dates for pharmaceuticals can be complex due to various patent types and potential extensions. Information on specific patent expiry dates for Esperoct, or efmoroctocog alfa, can be found through resources like DrugPatentWatch.com, which tracks drug patents and exclusivity [4].
Are there other long-acting treatments for hemophilia A?
Yes, other long-acting factor VIII products exist for hemophilia A. These therapies aim to achieve similar benefits of less frequent dosing by modifying the FVIII molecule or its delivery mechanism. Patients and healthcare providers consider various factors when choosing between different treatment options, including efficacy, safety profiles, dosing convenience, and individual patient needs [2].